Business Wire

JAPAN-SAKE-PR-SECRETARIA

25.7.2022 10:02:04 CEST | Business Wire | Press release

Share
Association de la Sommellerie Internationale’s new partner Japan Sake and Shochu Makers Association Invited to General Assembly in Japan

Japan Sake and Shochu Makers Association (hereafter, “JSS") concluded a partnership agreement with the Association de la Sommellerie Internationale (hereafter, “ASI”) in May this year.
JSS exchanged greetings at the ASI general assembly held at the “Nagoya Marriott Associa Hotel” in Japan on July 5 and 6, and joined the welcome dinner held the night before. There they had the opportunity to meet and greet representatives of sommelier associations from 22 countries who were visiting Japan. Welcome dinner cuisine was paired with wine and six varieties of Japanese sake.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719005658/en/

ASI members were invited to a two-day excursion organized by Mie Sake Brewers Association on July 7 and 8. Participants had the valuable opportunity to tour sake breweries in Mie Prefecture, visit the Ise Grand Shrine that is known for its historical links to sake, and explore the rich history and techniques used to make dashi soup stock at katsuobushi (bonito flakes) production plants.

A sake tasting and discussion event with the member breweries of the Mie Sake Brewers Association, followed by the International Sake Conference in Mie , were held in the evening of July 7 at the “Shima Kanko Hotel,” which attracted worldwide attention in 2016 as the venue for the G7 ISE-SHIMA SUMMIT. A panel discussion led by six panelists including ASI Chairman Wouters covered topics like the potential of Japanese sake as well as international initiatives being planned by JSS.
Representatives from sommelier associations around the world provided a broad range of feedback on how sake could be paired with various styles of cuisines, with many expressing that they would like to try sake with their own country’s culinary specialties.

The reception featured an eight-course meal fusing French cuisine with dashi-inspired flavors and paired with eight local brands of sake, in an ensemble featuring Mie’s three local specialties—ingredients, dashi and sake. This level of hospitality proved to be a source of amazement and inspiration for the leading international sommeliers who had the chance to savor the flavors provided.
The chairs of the Belgian, Serbian, Spanish, and Mexican sommelier associations expressed their desire to work with JSS and schedule sake master classes in the near feature, thus demonstrating the considerable interest that sommeliers have developed for sake.

Looking forward, JSS will coordinate efforts with ASI by providing sake tasting and seminars at events organized by ASI.

Japan Sake and Shochu Makers Association SNS links are as follows.
FB: https://www.facebook.com/japansakeshochu
IG: https://www.instagram.com/japansakeshochu_en/
YouTube: https://www.youtube.com/user/JapanSakeOfficial
Twitter: https://twitter.com/jss_sake_en

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye